Arizona State Retirement System lifted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 2.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 85,109 shares of the medical instruments supplier's stock after purchasing an additional 2,121 shares during the period. Arizona State Retirement System's holdings in Becton, Dickinson and Company were worth $19,495,000 at the end of the most recent reporting period.
A number of other hedge funds also recently made changes to their positions in the business. Norges Bank purchased a new stake in Becton, Dickinson and Company in the 4th quarter worth about $735,523,000. T. Rowe Price Investment Management Inc. increased its holdings in Becton, Dickinson and Company by 36.1% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 12,126,707 shares of the medical instruments supplier's stock worth $2,751,187,000 after acquiring an additional 3,219,317 shares during the last quarter. Kovitz Investment Group Partners LLC increased its holdings in Becton, Dickinson and Company by 392.4% in the 4th quarter. Kovitz Investment Group Partners LLC now owns 3,416,665 shares of the medical instruments supplier's stock worth $775,139,000 after acquiring an additional 2,722,829 shares during the last quarter. Massachusetts Financial Services Co. MA increased its holdings in Becton, Dickinson and Company by 15.1% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 6,175,899 shares of the medical instruments supplier's stock worth $1,401,126,000 after acquiring an additional 810,345 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in Becton, Dickinson and Company by 29,654.0% in the 1st quarter. GAMMA Investing LLC now owns 744,445 shares of the medical instruments supplier's stock worth $170,523,000 after acquiring an additional 741,943 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.
Becton, Dickinson and Company Price Performance
BDX opened at $175.87 on Friday. The stock has a fifty day simple moving average of $172.33 and a two-hundred day simple moving average of $205.91. The company has a current ratio of 1.13, a quick ratio of 0.64 and a debt-to-equity ratio of 0.70. The company has a market cap of $50.41 billion, a price-to-earnings ratio of 33.56, a price-to-earnings-growth ratio of 1.33 and a beta of 0.25. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.28 by $0.07. The business had revenue of $5.27 billion during the quarter, compared to the consensus estimate of $5.35 billion. Becton, Dickinson and Company had a return on equity of 15.99% and a net margin of 7.28%. The firm's quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.17 earnings per share. Research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.
Becton, Dickinson and Company Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Monday, June 30th. Stockholders of record on Monday, June 9th were given a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 2.37%. The ex-dividend date was Monday, June 9th. Becton, Dickinson and Company's dividend payout ratio is presently 79.39%.
Analysts Set New Price Targets
A number of research firms have weighed in on BDX. Wells Fargo & Company lowered Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a report on Thursday, May 1st. William Blair lowered Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a report on Thursday, May 1st. Morgan Stanley reduced their target price on Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating for the company in a report on Tuesday, May 6th. Raymond James Financial lowered Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a report on Friday, May 2nd. Finally, Bank of America lowered Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 price objective for the company. in a report on Thursday, May 1st. Eight analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $219.22.
Check Out Our Latest Stock Report on Becton, Dickinson and Company
Insider Activity
In other news, EVP David Shan sold 1,166 shares of Becton, Dickinson and Company stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $171.19, for a total value of $199,607.54. Following the completion of the transaction, the executive vice president owned 4,575 shares of the company's stock, valued at $783,194.25. The trade was a 20.31% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.36% of the stock is currently owned by corporate insiders.
About Becton, Dickinson and Company
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Articles
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
